

# Randomised controlled trial and cost effectiveness study of targeted screening versus systematic population screening for atrial fibrillation in the over 65s: the SAFE study

<b>Submission date</b> 25/04/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 25/04/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 13/01/2015	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof FD Richard Hobbs

**Contact details**  
Department of Primary Care & General Practice  
University of Birmingham  
The Medical School  
Birmingham  
United Kingdom  
B15 2TT  
+44 (0)121 415 8019  
f.d.r.hobbs@bham.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

## Secondary identifying numbers

HTA 96/22/11

# Study information

### Scientific Title

Randomised controlled trial and cost effectiveness study of targeted screening versus systematic population screening for atrial fibrillation in the over 65s: the SAFE study

### Acronym

SAFE

### Study objectives

1. To establish the incremental cost effectiveness of different screening options (targeted or population screening) compared with routine clinical practice for detection of AF in over 65s.
2. To determine the value of clinical factors and echocardiography in the process of risk stratification for thromboembolic disease in patients with AF.
3. To determine optimal method of AF diagnosis and ECG interpretation.
4. To assess implications for service provision should screening for AF become a national programme.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Screening

### Participant information sheet

### Health condition(s) or problem(s) studied

Cardiovascular diseases: Heart disease

### Interventions

Screening vs control.

24,000 patients aged over 65 will be identified from approximately 24 purposefully selected

general practices from the West Midlands. Patient randomisation will result in 5,000 patients invited for screening with 5,000 control patients from the same practice (Principal-control patients). Control practices will provide a further 4,000 control patients (Practice-controls). Prospective identification of pre-existing risk factors for AF within the screened population (estimated at 2,000 patients) will enable comparison between high risk targeted screening and total population screening. Study outcomes will identify the clinical and cost effectiveness of overall screening strategy (2 options compared), actual screening method (4 methods compared), and screening test interpretation (4 options evaluated).

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Not provided at time of registration.

**Secondary outcome measures**

Not provided at time of registration.

**Overall study start date**

01/06/2000

**Completion date**

31/05/2003

**Eligibility****Key inclusion criteria**

Patients over 65 years

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Both

**Target number of participants**

15,000

**Key exclusion criteria**

Not provided at time of registration.

**Date of first enrolment**

01/06/2000

**Date of final enrolment**

31/05/2003

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Department of Primary Care & General Practice

Birmingham

United Kingdom

B15 2TT

## Sponsor information

**Organisation**

Department of Health (UK)

**Sponsor details**

Quarry House

Quarry Hill

Leeds

United Kingdom

LS2 7UE

+44 (0)1132 545 843

Sheila.Greener@doh.gsi.gov.uk

**Sponsor type**

Government

**Website**

<http://www.dh.gov.uk/en/index.htm>

**ROR**

<https://ror.org/03sbpja79>

## Funder(s)

**Funder type**

Government

**Funder Name**

NIHR Health Technology Assessment Programme - HTA (UK)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	29/07/2004		Yes	No
<a href="#">Results article</a>	results	25/08/2007		Yes	No
<a href="#">Results article</a>	results	01/06/2014		Yes	No